Alumis (NASDAQ:ALMS) Shares Gap Up After Analyst Upgrade

Shares of Alumis Inc. (NASDAQ:ALMS) gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $18.00 to $32.00. The stock had previously closed at $16.23, but opened at $17.39. Guggenheim currently has a buy rating on the stock. Alumis shares last traded at $17.3610, with a volume of 2,599,676 shares.

Several other research analysts have also recently issued reports on ALMS. Leerink Partners increased their price target on Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Wells Fargo & Company increased their target price on shares of Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday. UBS Group reissued an “outperform” rating on shares of Alumis in a research note on Tuesday. Finally, HC Wainwright boosted their price target on shares of Alumis from $14.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.33.

Insider Transactions at Alumis

In other Alumis news, major shareholder Foresite Labs, Llc purchased 200,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were purchased at an average cost of $5.59 per share, for a total transaction of $1,118,000.00. Following the completion of the transaction, the insider owned 2,234,129 shares in the company, valued at $12,488,781.11. The trade was a 9.83% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Srinivas Akkaraju purchased 276,179 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was acquired at an average cost of $5.25 per share, with a total value of $1,449,939.75. Following the completion of the acquisition, the director directly owned 276,179 shares in the company, valued at $1,449,939.75. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 2,788,875 shares of company stock valued at $18,352,357 in the last three months. 40.70% of the stock is currently owned by insiders.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Envudeucitinib met all primary and key secondary endpoints in two Phase III plaque psoriasis studies, driving strong efficacy headlines and a roughly 95% intraday share reaction as investors price in commercial potential. ALMS Surges as Envudeucitinib Meets Goals in Plaque Psoriasis Studies
• Positive Sentiment: Multiple analysts bumped targets and issued buy/overweight ratings after the clinical readouts (examples include Guggenheim, Morgan Stanley, Wells Fargo), lifting consensus upside and momentum. Higher price targets support further upside expectations. What’s Going On With Alumis Stock Thursday?
• Neutral Sentiment: Alumis priced an upsized underwritten offering of 17.65 million shares at $17.00 per share (approx. $300M gross proceeds) and granted a 30‑day option to buy an additional 2.6475 million shares; the deal is expected to close around Jan. 9, 2026. This is a financing to advance the pipeline but is a material capital raise. Alumis Announces Pricing of Upsized Public Offering of Common Stock
• Negative Sentiment: The offering is entirely new shares sold by the company, meaning significant dilution for existing shareholders; issuing 17.65M shares (plus option) can weigh on near-term per‑share metrics and valuation. Alumis Inc. Announces Pricing of Upsized Public Offering
• Negative Sentiment: Heavy trading and rapid price gains increase short-term volatility risk; some investors may take profits after the clinical-driven rally while others reassess post-offering share count and forward guidance. Alumis up 95% on envudeucitinib results in psoriasis

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Stonepine Capital Management LLC acquired a new position in shares of Alumis in the second quarter worth about $1,049,000. Trium Capital LLP raised its holdings in shares of Alumis by 17.9% during the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock valued at $12,457,000 after acquiring an additional 474,072 shares during the period. General Atlantic L.P. purchased a new stake in shares of Alumis in the 2nd quarter valued at approximately $3,893,000. Velan Capital Investment Management LP purchased a new stake in shares of Alumis in the 2nd quarter valued at approximately $4,863,000. Finally, Los Angeles Capital Management LLC acquired a new position in Alumis in the 2nd quarter worth approximately $368,000.

Alumis Trading Up 1.5%

The firm’s 50-day simple moving average is $8.92 and its two-hundred day simple moving average is $5.80. The stock has a market capitalization of $1.90 billion, a PE ratio of -4.49 and a beta of -2.09.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The firm had revenue of $2.07 million for the quarter, compared to analyst estimates of $3.14 million. As a group, research analysts expect that Alumis Inc. will post -8.51 earnings per share for the current year.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.